Health & Biotech
World renowned psychedelics experts join Incannex’s Clarion Clinics advisory board
Health & Biotech
ASX Health Stocks: Neurotech gets approval to treat children patients until they are 20 years old
Health & Biotech
ASX biotechs are looking up, and the FDA breakthroughs are starting to flow
Health & Biotech
ASX Health Stocks: Tissue Repair and Radiopharm jump double digits after US FDA meetings
Health & Biotech
Wellnex to buy leading Australian pain relief brand Pain Away for $22 million
Health & Biotech
ScoPo’s Powerplays: ASX health stocks fall as investors fail to reward good news
Health & Biotech
Check Up: Here’s how diabetes drugs can help you get off the beers and lose weight
Health & Biotech
ASX Health Stocks: Patrys, Immutep jump after reports show drugs well tolerated
Health & Biotech
ASX Health Stocks: 4DMedical makes breakthrough, potentially disrupts century-old method
Health & Biotech
Pop the champagne as EBR becomes latest ASX biotech to achieve key catalyst
Health & Biotech
PharmAust confirms safety of MPL, poised to up dosage in MND trial
Health & Biotech
Orphan drug designation has a direct impact on drug pricing for these pharma players
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.